Clinical trials
First-Line clinical trials
Below are recruiting first-line clinical trials, each written for real people, not researchers. We’re tracking 399 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06459687RecruitingPhase 3
Socazolimab for first-line treatment of advanced cervical cancer
This phase 3 trial tests a new immunotherapy drug called socazolimab combined with chemotherapy as a first treatment for cervical cancer that has come back, spread, or cannot be removed with surgery or radiation. The goal is to see if it helps shrink tumors and improves survival.
Hefei, AnhuiAges 18–75 - NCT07085767RecruitingPhase 3
Palazestrant and ribociclib for first-line advanced breast cancer
This trial tests a new drug (palazestrant) combined with ribociclib for people with a common type of advanced breast cancer that is estrogen receptor-positive and HER2-negative. You may qualify if you haven't had treatment for advanced disease and your cancer has either just been found or came back long after completing hormone therapy.
Hot Springs, ArkansasAges 18 years+ - NCT07088211RecruitingPhase 2
New drug combo for first-line head and neck cancer
This trial tests a new drug combination (sacituzumab tirumotecan and toripalimab) as a first treatment for people with advanced head and neck squamous cell carcinoma that cannot be removed with surgery. The goal is to see if this treatment shrinks tumors and improves outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06574347RecruitingPhase 2
Two targeted drugs for EGFR-mutated, MET-high lung cancer
This trial tests a combination of two targeted drugs (vebreltinib and PLB1004) as the first treatment for people with a specific type of advanced lung cancer that has both an EGFR mutation and high MET protein. It may offer a new option for those who haven't had treatment yet.
Guangzhou, GuangdongAges 18 years+ - NCT07070648Recruiting
Predicting DLBCL treatment response with ctDNA and PET scans
This trial uses a blood test (ctDNA) and PET scans to predict how well standard first-line treatment works for diffuse large B-cell lymphoma (DLBCL). It aims to find out if these tests can guide better care.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07063745RecruitingPhase 2/Phase 3
Comparing a new drug combo for advanced lung cancer with a specific gene change
This trial tests a new drug called Navlimetostat combined with pembrolizumab and chemotherapy versus a placebo with the same standard treatments. It is for people with metastatic non-small cell lung cancer that has a specific missing gene (MTAP deletion) and who have not had prior treatment for their advanced disease.
Anchorage, AlaskaAges 18 years+ - NCT07060014RecruitingPhase 1
Testing NALIRIFOX for advanced appendix and small intestine cancer
This trial tests a combination of four chemotherapy drugs (NALIRIFOX) as a first treatment for people with advanced appendix or small intestine cancer. It aims to see if this combination is safe and effective.
Houston, TexasAges 18 years+ - NCT07061535RecruitingPhase 2
Sintilimab, tafolecimab and chemo for advanced small cell lung cancer
This trial tests a combination of two immunotherapy drugs (sintilimab and tafolecimab) plus standard chemotherapy as a first treatment for extensive-stage small cell lung cancer. The goal is to see if adding these drugs helps people live longer and have better outcomes.
Changsha, HunanAges 18 years+ - NCT07062263RecruitingPhase 3
Trastuzumab with chemo for HER2+ bile duct cancer
This trial tests if adding trastuzumab to standard chemotherapy can help people with advanced bile duct or gallbladder cancer that tests positive for HER2. The study aims to see if the combination works better than chemotherapy alone.
Muzaffarpur, BiharAges 18–99 - NCT06992128RecruitingPhase 2
Romiplostim plus steroids for newly diagnosed ITP
This trial tests a combination of romiplostim (a platelet-boosting drug) and steroids as the first treatment for adults with newly diagnosed immune thrombocytopenia (ITP). It aims to see if this approach can safely and effectively raise platelet counts.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07054307RecruitingPhase 1
Study of MRG003 plus HX008 for EGFR-positive penile cancer
This trial tests two drugs, MRG003 and HX008, as a first treatment for men with EGFR-positive penile squamous cell carcinoma that cannot be removed by surgery or has spread. The goal is to see if the combination shrinks tumors or delays growth.
Chengdu, SichuanAges 18 years+ - NCT06429696RecruitingPhase 2
Maintenance therapy for extensive stage small cell lung cancer
This study tests if a combination of an immunotherapy drug (PD-L1 inhibitor) and a targeted therapy pill (apatinib) can help keep extensive stage small cell lung cancer from growing after initial treatment. It is for people whose cancer was controlled with first-line chemo-immunotherapy.
Guangzhou, GuangdongAges 18–75 - NCT06157996RecruitingPhase 2
Lenvatinib, Tislelizumab, and CapeOX for advanced stomach cancer
This trial tests a combination of three drugs (lenvatinib, tislelizumab, and CapeOX chemotherapy) as the first treatment for advanced stomach or gastroesophageal junction cancer that is PD-L1 positive and has a low TMEscore. The goal is to see if this combination helps control the cancer better than standard treatments.
Guangzhou, GuangdongAges 18 years+ - NCT07015242RecruitingPhase 2
Liso-cel as first treatment for primary CNS lymphoma
This study tests an investigational cell therapy called liso-cel for people with primary central nervous system lymphoma who cannot have a stem cell transplant and have already responded to initial chemotherapy. The goal is to see if liso-cel can help control the disease better and possibly improve outcomes.
Aurora, ColoradoAges 18 years+ - NCT07022223RecruitingPhase 2
Orelabrutinib plus rituximab for first treatment of marginal zone lymphoma
This trial tests a combination of two targeted drugs, orelabrutinib and rituximab, as the first systemic treatment for marginal zone lymphoma. If you have not yet had chemotherapy for your lymphoma and meet certain health criteria, you may be able to join.
Hangzhou, ZhejiangAges 18 years+ - NCT07018037Recruiting
TTV levels during first immunotherapy for kidney cancer
This study looks at whether a virus called TTV (torque teno virus) in the blood can help predict how well immunotherapy works for advanced kidney cancer. If you have clear cell renal cell carcinoma that has spread and are about to start your first immunotherapy, you may be able to join.
Rome, RomeAges 18 years+ - NCT07005102RecruitingPhase 2/Phase 3
Telisotuzumab adizutecan and osimertinib for EGFR-positive lung cancer
This trial tests a new drug combination (telisotuzumab adizutecan plus osimertinib) as a first treatment for adults with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination is safe and works better than standard care.
Chandler, ArizonaAges 18 years+ - NCT07007962RecruitingPhase 3
Oral pill for immune thrombocytopenia after first treatment fails
This trial tests an oral medicine called rilzabrutinib for adults with immune thrombocytopenia (ITP) whose first treatment stopped working or who need steroids long-term. The goal is to see if it helps raise platelet counts and reduce bleeding risk.
Clovis, CaliforniaAges 18 years+ - NCT07008235RecruitingPhase 2/Phase 3
Testing two drugs for upset stomach relief
This trial tests whether a combination of two medications, amitriptyline and trifluoperazine, can help patients with ongoing discomfort in the upper stomach (functional dyspepsia). It may be an option if other treatments haven't worked.
DhakaAges 18–60 - NCT07002346RecruitingPhase 3
Immunotherapy and bevacizumab for advanced ovarian clear cell cancer
This trial tests a combination of an immunotherapy drug (QL1706) and a targeted therapy (bevacizumab) for women with newly diagnosed advanced ovarian clear cell carcinoma. The goal is to see if this combination works better than standard treatment after surgery.
Wuhan, HubeiAges 18–75 - NCT07000253RecruitingPhase 2
Timing of local treatment for limited metastatic stomach or esophageal cancer
This trial tests whether giving local treatments (like surgery or radiation) to cancer spots later—after starting immunotherapy or targeted therapy—helps people with stomach or esophageal cancer that has spread to a few places. It aims to improve outcomes by timing treatments carefully.
AmsterdamAges 18 years+ - NCT06494995RecruitingPhase 2
AK104 and low-dose radiation for advanced head and neck cancer
This trial tests a new immunotherapy drug called AK104 (cadonilimab) combined with low-dose radiation for people with head and neck or nasopharyngeal cancer that has come back or spread and no longer responds to first treatment. The goal is to see if this combination can shrink tumors or stop them from growing.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06989112RecruitingPhase 3
First-line treatment for advanced or recurrent endometrial cancer
This trial tests a new combination of drugs for endometrial cancer that has spread or come back. It aims to see if these drugs can shrink tumors and help people live longer. It is for tumors that have a certain protein (HER2) and are mismatch repair proficient (meaning they have a normal DNA repair system).
Tucson, ArizonaAges 18 years+ - NCT06969612RecruitingPhase 1
New drug combo as first treatment for advanced lung cancer
This trial tests a new combination of three medicines (Golidocitinib, Tislelizumab, and chemotherapy) as the first treatment for advanced non-small cell lung cancer (NSCLC). It is designed for people whose tumors have at least 1% PD-L1 and who have not had any previous treatment for advanced disease.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new First-Line trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for first-line?
- Yes. Clin2 currently lists 399 recruiting first-line studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a first-line trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a first-line trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.